Cargando…

Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients

PURPOSE: Thyroid hormone receptors (THR) have manifold functions and are involved in the carcinogenesis of several tumor types. Within this study, we aimed to investigate the expression pattern (nuclear versus cytoplasmic) of the THR alpha and its impact on patients survival in ovarian cancer (OvCa)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ditsch, Nina, Heublein, Sabine, Jeschke, Udo, Sattler, Cornelia, Kuhn, Christina, Hester, Anna, Czogalla, Bastian, Trillsch, Fabian, Mahner, Sven, Engel, Jutta, Mayr, Doris, Schmoeckel, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324415/
https://www.ncbi.nlm.nih.gov/pubmed/32533406
http://dx.doi.org/10.1007/s00432-020-03241-7
_version_ 1783551937614970880
author Ditsch, Nina
Heublein, Sabine
Jeschke, Udo
Sattler, Cornelia
Kuhn, Christina
Hester, Anna
Czogalla, Bastian
Trillsch, Fabian
Mahner, Sven
Engel, Jutta
Mayr, Doris
Schmoeckel, Elisa
author_facet Ditsch, Nina
Heublein, Sabine
Jeschke, Udo
Sattler, Cornelia
Kuhn, Christina
Hester, Anna
Czogalla, Bastian
Trillsch, Fabian
Mahner, Sven
Engel, Jutta
Mayr, Doris
Schmoeckel, Elisa
author_sort Ditsch, Nina
collection PubMed
description PURPOSE: Thyroid hormone receptors (THR) have manifold functions and are involved in the carcinogenesis of several tumor types. Within this study, we aimed to investigate the expression pattern (nuclear versus cytoplasmic) of the THR alpha and its impact on patients survival in ovarian cancer (OvCa). METHODS: The presence of the thyroid hormone receptors THRα, THRα1 and − 2 was investigated in 156 ovarian cancer samples using immunohistochemistry (IHC) using semi-quantitative immunoreactivity (IR) scores and correlated with clinical, pathological data, subtype of ovarian cancer, clinical data, staining of 20 already described OvCa marker proteins and overall survival (OS). RESULTS: Among all subtypes of OvCa, clear cell carcinomas showed the highest THRα expression. Furthermore, nuclear THRα was associated with a reduced survival in this subtype. However, nuclear expressed THRα1 turned out to be a positive prognosticator for all subtypes of OvCa patients. Nuclear THRα2 is a positive prognosticator for OvCa patients of the serous subtype. In contrast, cytoplasmic expression THRα2 was associated with a reduced OS in all subtypes of OvCa patients; while, cytoplasmic expression of THRα1 is associated with reduced OS in mucinous OvCa patients only. In addition, THRα expression correlates with gonadotropin receptors, steroid hormone receptors, TA-MUC1 and glycodelin. CONCLUSION: Depending on nuclear or cytoplasmic expression, our study shows that THRα and its isoforms 1 and 2 provide different prognostic information for ovarian cancer patients. Further investigations should analyze if THRs may represent new endocrine targets for the treatment of ovarian cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-020-03241-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7324415
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-73244152020-07-07 Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients Ditsch, Nina Heublein, Sabine Jeschke, Udo Sattler, Cornelia Kuhn, Christina Hester, Anna Czogalla, Bastian Trillsch, Fabian Mahner, Sven Engel, Jutta Mayr, Doris Schmoeckel, Elisa J Cancer Res Clin Oncol Original Article – Cancer Research PURPOSE: Thyroid hormone receptors (THR) have manifold functions and are involved in the carcinogenesis of several tumor types. Within this study, we aimed to investigate the expression pattern (nuclear versus cytoplasmic) of the THR alpha and its impact on patients survival in ovarian cancer (OvCa). METHODS: The presence of the thyroid hormone receptors THRα, THRα1 and − 2 was investigated in 156 ovarian cancer samples using immunohistochemistry (IHC) using semi-quantitative immunoreactivity (IR) scores and correlated with clinical, pathological data, subtype of ovarian cancer, clinical data, staining of 20 already described OvCa marker proteins and overall survival (OS). RESULTS: Among all subtypes of OvCa, clear cell carcinomas showed the highest THRα expression. Furthermore, nuclear THRα was associated with a reduced survival in this subtype. However, nuclear expressed THRα1 turned out to be a positive prognosticator for all subtypes of OvCa patients. Nuclear THRα2 is a positive prognosticator for OvCa patients of the serous subtype. In contrast, cytoplasmic expression THRα2 was associated with a reduced OS in all subtypes of OvCa patients; while, cytoplasmic expression of THRα1 is associated with reduced OS in mucinous OvCa patients only. In addition, THRα expression correlates with gonadotropin receptors, steroid hormone receptors, TA-MUC1 and glycodelin. CONCLUSION: Depending on nuclear or cytoplasmic expression, our study shows that THRα and its isoforms 1 and 2 provide different prognostic information for ovarian cancer patients. Further investigations should analyze if THRs may represent new endocrine targets for the treatment of ovarian cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-020-03241-7) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-06-12 2020 /pmc/articles/PMC7324415/ /pubmed/32533406 http://dx.doi.org/10.1007/s00432-020-03241-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article – Cancer Research
Ditsch, Nina
Heublein, Sabine
Jeschke, Udo
Sattler, Cornelia
Kuhn, Christina
Hester, Anna
Czogalla, Bastian
Trillsch, Fabian
Mahner, Sven
Engel, Jutta
Mayr, Doris
Schmoeckel, Elisa
Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients
title Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients
title_full Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients
title_fullStr Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients
title_full_unstemmed Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients
title_short Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients
title_sort cytoplasmic versus nuclear thr alpha expression determines survival of ovarian cancer patients
topic Original Article – Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324415/
https://www.ncbi.nlm.nih.gov/pubmed/32533406
http://dx.doi.org/10.1007/s00432-020-03241-7
work_keys_str_mv AT ditschnina cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT heubleinsabine cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT jeschkeudo cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT sattlercornelia cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT kuhnchristina cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT hesteranna cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT czogallabastian cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT trillschfabian cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT mahnersven cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT engeljutta cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT mayrdoris cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients
AT schmoeckelelisa cytoplasmicversusnuclearthralphaexpressiondeterminessurvivalofovariancancerpatients